Truvelog Mix 30 Withdrawal: EU Commission Steps in as Sanofi Discontinues Insulin Product

The European Commission has officially withdrawn the marketing authorisation for Truvelog Mix 30, an insulin aspart product, following a request from its manufacturer Sanofi Winthrop Industrie. The withdrawal, announced on 25 January 2024, is attributed to the company’s decision to discontinue the product for commercial reasons.

Truvelog Mix 30 was granted marketing approval in the EU on 25 April 2022, aimed at treating diabetes mellitus in adults and children aged ten and above. The medication was categorized as a biosimilar, meaning it is designed to be highly similar to an already approved biological treatment.

The significance of this withdrawal for diabetes patients and healthcare providers is notable, as it alters the treatment landscape for insulin therapies in the EU. Such discontinuations can impact patient choices and treatment protocols, especially for those dependent on specific medications.

Moving forward, the European Public Assessment Report (EPAR) for Truvelog Mix 30 will be updated to reflect the current status of the marketing authorisation, marking it as invalid. Healthcare providers and patients will need to seek alternative treatments, emphasizing the importance of staying informed about medication availability.

This decision reinforces the dynamic nature of pharmaceutical approvals and market presence, where commercial viability plays a critical role in the continued availability of medical products.